Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CDC42 | P60953 | 1/20 | 0.49 |
| ▸ | RAC1 | P63000 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23298286 | 1.00 | LDHA (0.50) | LDHAAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL7082950 | 1.00 | LDHA (0.50) | LDHAAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL30404277 | 1.00 | LDHA (0.50) | LDHAAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL18325177 | 0.83 | AKR1C3 (0.51) | LDHAAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL18082663 | 0.83 | AKR1C3 (0.51) | LDHAAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL8022182 | 0.83 | AKR1C3 (0.51) | LDHAAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL10480695 | 0.83 | RAB9A (0.47) | CA1CA2AOC3CES2CES1 | |
| SCHEMBL7082815 | 0.83 | RAB9A (0.47) | CA1CA2AOC3CES2CES1 | |
| SCHEMBL9322760 | 0.81 | ACHE (0.64) | LDHAAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL16119284 | 0.81 | ACHE (0.64) | LDHAAKR1C3AKR1C2PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024102421-A2 | COMPOUNDS, COMPLEXES, AND METHODS FOR THEIR PREPARATION AND OF THEIR USE | Revolution Medicines, Inc. (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4334324-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| EP-4208261-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022235866-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2022-11-10 | — | — | WO | disclosed |
| CN-114901366-A | RAS inhibitors | 锐新医药公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20210130326-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| US-6881839-B2 | Process for preparing diltiazem using a heterogeneous trifunctional catalyst | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-04-19 | — | — | US | disclosed |
| US-20040127704-A1 | Process for preparing diltiazem using a heterogeneous trifunctional catalyst | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | LDHA 4546/4885AKR1C3 3360/4885AKR1C2 3223/4885 |
| US-20210130326-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | LDHA 4330/4885AKR1C3 4025/4885AKR1C2 3878/4885 |
| US-20040127704-A1 | Process for preparing diltiazem using a heterogeneous trifunctional catalyst | CYP2W1, INMT, TST | LDHA 1660/4885AKR1C3 1693/4885AKR1C2 1336/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | LDHA 2952/4885AKR1C3 3936/4885AKR1C2 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.